THE OPPORTUNITY: Therapies Targeting STAT3 Inhibition
Chairman, Co-Founder
Chief Medical Officer
Developed 10 drugs which are currently in the market. For example, Enalapril (Vasotec) and Lisinopril (Prinivil/Zestril
Former CEO & President of Transcend Therapeutics Inc. Former Vice President of Medical Affairs for Vertex Pharmaceuticals Inc.
Former Executive Director at Novartis (formerly known as Ciba-Geigy Corporation. Former Senior Director at Merck/MSDRL Corporation.
He served as the Chairman of the Board of Directors of DNAPrint Genomics Inc.
Scientific Advisor for Athena Capital Partners Inc.
Richard H. Gabriel B.S., MBA
CEO, President,
Co-Founder
Former President of Calix Corporation, parent company to Pharm-Eco Laboratories Inc. From 2004 until 2008.
Chief Executive Officer and President for DNAPrint Genomics Inc.
Successfully completed formation of several private and public companies in the genetics, chemistry and pharmaceutical fields.
Has been a part of the development of four successful drugs that include: Amprenavir (VX-478), Emtricitabine (FTC), Altretamine (Hexalen), Zalcitabine (DDC).
Former CEO of DNAPrint genomics, Inc., which made history and earned international media attention by developing innovative consumer and forensic genomics products.
Executive manager of both private and public traded companies.
Founder and CEO of Okeanos Technologies.
Thought leader in the life sciences.
Author of graduate level textbook on Human Genomics, dozens of conference presentations, publications and patents.
Led development and commercialization of over 45 diagnostic products including 22 oncology assays.
Research Director and Research Fellow at DuPont Medical Products and Dade Behring Diagnostics leading to over $200M in product sales.
Director of Project Management at DuPont Pharmaceuticals leading Personalized Medicine Team.
Director or Technology and Project Management at Diagnostic Oncology, CRO leading to over $150M in client product sales.
Founder and CEO of Biomarker Associates, Inc. supporting development and commercialization of new products at 8 technology startup companies and 3 major diagnostic companies
Richard Jove, PhD; Emeritus Director of the Beckman Institute & Oncology Division Director at City of Hope, Duarte CA and now President and Director, Vaccine & Gene Therapy Institute Port Saint Lucie, Florida
David Frank, MD, PhD Associate Professor, Department of Medicine, Harvard Medical School. Associate Professor of Medicine, Medical Oncology, Dana Farber Cancer Center, Boston